LightWave Acquisition Aktie - LWAC

LightWave Acquisition Corporation (LWAC) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

10,20

( - )

Gebot

3,91

Fragen

10,27

Volumen

10,25 Tagesbereich 10,25

9,8068 52-Wochen-Bereich 16,98

Marktkapitalisierung

306,765M

Handelsende

10,20

Handelsbeginn

10,25

Letzte Trade

10.25

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

US$ 13.067

Ausgegebene Aktien

30.075.000

Dividendenrendite (LTM)

Kurs-Gewinn-Verhältnis

Gewinn pro Aktie (EPS)

Erlöse (LTM)

Nettogewinn (LTM)

3,96M

LightWave Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. LightWave Acquisition Corp. was incorporated in 20... LightWave Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. LightWave Acquisition Corp. was incorporated in 2025 and is based in Dallas, Texas. Mehr anzeigen

Sektor

Branche

Website

lightwaveacquisition.com

Hauptsitz

Dallas, United States

Gegründet

2026

LightWave Acquisition Corporation is listed in the sector of the NASDAQ with ticker LWAC. The last closing price for LightWave Acquisition was US$10,20. Over the last year, LightWave Acquisition shares have traded in a share price range of US$ 9,8068 to US$ 16,98.

LightWave Acquisition currently has 30.075.000 shares in issue. The market capitalisation of LightWave Acquisition is US$306,77 million.

LightWave Acquisition Corp. Announces Closing of $215,625,000 Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option

Dallas, TX, June 26, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the “Company”), a newly organized special purpose acquisition...

LightWave Acquisition Corp. Announces Pricing of $187,500,000 Initial Public Offering

Dallas, TX, June 24, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the “Company”), a newly organized special purpose acquisition...

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the...

Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ: LWAC) (“LWAC” or the “Company”), a special purpose...

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of...

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of...

Locust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report ...

BOSTON, June 03, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ: LWAC) (the “Company”), a blank-check company formed for the...

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation ...

Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	10.2	10.25	10.2	5876	10.2000434	CS
4	-0.0099	-0.0969647107219	10.2099	10.29	10.2	6859	10.20059852	CS
12	0	0	10.2	10.29	10.155	7010	10.18376975	CS
26	0.17	1.69491525424	10.03	10.29	10.03	26051	10.10444103	CS
52	-6.78	-39.9293286219	16.98	16.98	9.8068	33299	10.04683631	CS
156	-6.78	-39.9293286219	16.98	16.98	9.8068	11129	10.04683631	CS
260	0.31	3.13447927199	9.89	29.2	8.33	18183	12.39320042	CS

LWAC - Frequently Asked Questions (FAQ)

What is the current LightWave Acquisition Corporation share price?

The current share price of LightWave Acquisition Corporation is US$ 10,20

How many LightWave Acquisition Corporation shares are in issue?

LightWave Acquisition Corporation has 30.075.000 shares in issue

What is the market cap of LightWave Acquisition Corporation?

The market capitalisation of LightWave Acquisition Corporation is USD 306,77M

What is the 1 year trading range for LightWave Acquisition Corporation share price?

LightWave Acquisition Corporation has traded in the range of US$ 9,8068 to US$ 16,98 during the past year

What is the registered address of LightWave Acquisition Corporation?

The registered address for LightWave Acquisition Corporation is 14755 Preston Road, Dallas, Texas, 75254

What is the LightWave Acquisition Corporation website address?

The website address for LightWave Acquisition Corporation is lightwaveacquisition.com

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

LightWave Acquisition Corporation (LWAC)

LightWave Acquisition Corporation (LWAC) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über LightWave Acquisition Corporation

LWAC Neueste Nachrichten

LightWave Acquisition Corp. Announces Closing of $215,625,000 Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option

LightWave Acquisition Corp. Announces Pricing of $187,500,000 Initial Public Offering

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

Locust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report ...

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation ...

LWAC - Frequently Asked Questions (FAQ)

LWAC Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

LightWave Acquisition Corporation (LWAC)

LightWave Acquisition Corporation (LWAC) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über LightWave Acquisition Corporation

LWAC Neueste Nachrichten

LightWave Acquisition Corp. Announces Closing of $215,625,000 Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option

LightWave Acquisition Corp. Announces Pricing of $187,500,000 Initial Public Offering

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

Locust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report ...

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation ...

LWAC - Frequently Asked Questions (FAQ)

LWAC Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen